Radiologists using FDA-approved AI tools for breast cancer detection report underwhelming results that diverge sharply from vendor promises. A Society of Breast Imaging survey of 215 members found that about half now deploy these systems clinically, but performance lags expectations across nearly every metric.

The data reveals a consistent shortfall. Only 35 percent of surveyed radiologists reported lower recall rates, yet 59 percent had expected the tools to deliver this benefit. Recall rates measure how often screening detects actual cancers. Higher recalls mean more false positives and unnecessary follow-up biopsies for patients. Lower recalls would reduce patient anxiety and healthcare costs. The 24-point gap between expected and actual performance illustrates the disconnect between marketing claims and clinical reality.

This pattern repeats across other measured categories, though the survey didn't specify which additional metrics disappointed. The gap suggests vendors may have overstated algorithm capabilities during FDA approval or marketing phases, or radiologists held unrealistic expectations about how much AI could improve their existing practices.

The timing matters. FDA-approved breast cancer detection AI tools emerged over the past five years, with major players including IBM Watson for Oncology, Hologic's SuperResolution, and GE Healthcare's AI-powered mammography platforms. These systems analyze mammograms to flag suspicious regions and estimate cancer probability. The regulatory pathway focused on sensitivity (catching cancers) rather than reducing false positives, a weakness many radiologists apparently didn't anticipate.

The survey's results point to a broader adoption reality in medical AI. Tools approved by regulators don't automatically translate to improved clinical workflows or outcomes. Radiologists still require training to interpret AI outputs effectively. Integration challenges, software usability, and alert fatigue from false positives can limit real-world benefit.

This doesn't mean breast cancer detection AI lacks value. The tools perform adequately as second readers for some